Topiramate: A prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy

Epileptic Disorders

Volumn 7, Issue 3, 2005, Pages 237-248

  Fröscher, Walter ^a   Schier, Katja R ^a   Hoffmann, Markus ^b   Meyer, Andreas ^a   May, Theodor W ^c   Rambeck, Bernhard ^c   Rösche, Johannes ^a  

^a Die Weissenau   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c Epilepsy Research Foundation   (Germany)

Author keywords

Adverse events; Cognition; Dosage; Serum concentration; Topiramate

Indexed keywords

ACETAZOLAMIDE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; SULTIAME; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; AGED; AGGRESSIVENESS; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DYSPNEA; EDEMA; EPILEPSY; EXHAUSTION; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; IRRITABILITY; LEUKOPENIA; MAINTENANCE DRUG DOSE; MALE; MEMORY DISORDER; MENTAL INSTABILITY; NAUSEA; NERVOUSNESS; PARESTHESIA; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SKIN DEFECT; SOMNOLENCE; SPEECH DISORDER; TREMOR; URINE INCONTINENCE; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 25844528587     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Abou-Khalil B, Topiramate YOL Study Group. Topiramate in the long-term management of refractory epilepsy. Epilepsia 2000; 41 (suppl 1): S72-S76.
2. Arroyo S, Squires L, Twyman R. Topiramate (TPM) monotherapy in newly diagnosed epilepsy: effectiveness in dose-response study. Epilepsia 2000; 43 (suppl 8): 47-8.
3. Arroyo S, Squires L, Wang S, Twyman R. Topiramate effective as monotherapy in dose-response study in newly diagnosed epilepsy. Epilepsia 2002; 43 (suppl 7): 241.
4. Ben-Menachem E, Squires L, Wang S, Thienel U. Topiramate as first-line monotherapy: tolerability and safety in 1000+ epilepsy patients. Epilepsia 2003; 44 (suppl 8): 152-3.
5. Berry DJ, Patsalos PN. Comparison of topiramate concentrations in plasma and serum by fluorescence polarization immunoassay. Ther Drug Monit 2002; 22: 460-4.
6. Biton V, Edwards KR, Montouris GD, et al. Topiramate titration and tolerability. Ann Pharmacother 2001; 35: 173-9.
7. Burcet-Dardé J. Use of topiramate in monotherapy and evaluation of plasma levels. Epilepsia 2002; 43: 146.
8. Chadwick DW, Wu SC, Pledger G. Post-titration seizure control with topiramate (TPM) as early/initial monotherapy. Epilepsia 1999; 40 (suppl 7): 111.
9. Christensen J, Andreasen F, Poulsen JH, Dam M. Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy. Neurology 2003; 61: 1210-8.
10. Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 2002; 24: 332-7.
11. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999; 40: 590-600.
12. Diaz-Obregon MD, Bathal H, Santiago R. Cognitive function in epilepsy patients controlled on monotherapy with topiramate. Epilepsia 2002; 43 (suppl 8): 169.
13. Dlugos DJ, Squires L, Wang S. Neurobehavioural adverse events (AES) with topiramate monotherapy in children and adolescents. Epilepsia 2003; 44 (suppl 8): 91-2.
14. Dodson WE, Kamin M, Kraut L, Olson WH, Wu SC. Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann Pharmacother 2003; 37: 615-20.
15. Donati F, Pfaeffli C, Ramelli GP. Adverse events due to antiepileptic drugs: results depending on the method of questioning. Epilepsia 2000; 41: 108.
16. Ferrari AR, Guerrini R, Gatti G, Alessandrimg, Bonanni P, Perucca E. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit 2003; 25: 700-8.
17. Fröscher W, Krämer G, Schmidt D, Stefan H. Serumkonzentration von Antiepileptika - praktische Richtlinien zur Messung und sinnvollen Interpretation (Serum concentration of antiepileptic drugs: guidelines for therapeutic monitoring and appropriate interpretation). Nervenarzt 1999; 70: 172-7.
18. Fröscher W, Schier KR, Hoffmann M, et al. Topiramat: Prospektive Untersuchung zur Frage der Korrelation von Serumkonzentration, Dosis und Nebenwirkungen. Z Epileptol 2004; 17: 160-1.
19. Gilliam FG, Veloso F, Bomhof MAM, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003; 60: 196-202.
20. Gilliam FG, Fessier AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects - a randomized trial. Neurology 2004; 62: 23-7.
21. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia 2000; 41 (suppl 8): S6-S15.
22. Grudzinski AN, Hakim Z, Coons SJ, Labiner DM. Use of the QOLIE-31 in routine clinical practice. J Epilepsy 1998; 11: 34-47.
23. Guberman A, Neto W, Gassmann-Mayer C. the EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002; 106: 183-9.
24. Jette NJ, Marson AG, Hutton JL. Topiramate add-on for drug-resistant partial epilepsy. The Cochrane database of symptomatic reviews (electronic resource) (3); p CD001417/2002.
25. Kellett MW, Smith DF, Stockton PA, Chadwick DW. Topiramate in clinical practice: First year's post-licensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999; 66: 759-63.
26. Kelly K, Stephen LJ, Sills GJ, Brodie MJ. Topiramate in patients with learning disability and refractory epilepsy. Epilepsia 2002; 43: 399-402.
27. Kockelmann E, Helmstaedter C, Elger CE. Comparative cognitive effects of topiramate and lamotrigine. Evidence for idiosyncratic and not serum level dependent cognitive impairment on TPM patients with epilepsy. Akt Neurol 2002; 29 (suppl 2): S190.
28. Kockelmann E, Elger CE, Helmstaedter C. Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: Relationships to blood serum levels and comedication. Epilepsy Behav 2004; 5: 716-21.
29. Krakow K, Schreiner A. Efficacy and tolerability of topiramate as an early add-on therapy in 450 patients with epilepsy. Epilepsia 2003; 44 (suppl 8): 172.
30. Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54: 752-73.
31. Lathers CM, Schraeder PK, Claycamp HG. Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios. J Clin Pharmacol 2003; 43: 491-503.
32. May TW, Rambeck B, Jürgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit 2002; 24: 366-74.
33. Mikaeloff Y, de Saint-Martin A, Mancini J, et al. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003; 53: 225-32.
34. Montouris GD, Biton V, Rosenfeld WE, Topiramate YTC/YTCE Study Group. Nonfocal generalized tonic-clonic seizures: response during long-term topiramate treatment. Epilepsia 2000; 41 (suppl 1): S77-S81.
35. Mula M, Trimble MR, Lhatoo SD, Sander JWAS. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003; 44: 659-63.
36. Nagel BJ, Brewer VR, Phelphs SJ. Cognitive and behavioural side effects associated with topiramate. J Pediatr Pharmacol Ther 2001; 6: 258-70.
37. Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs. Epilepsy Behav 2004; 5: S60-S65.
38. Patsalos PN. New antiepileptic drugs. Ann Clin Biochem 1999; 36: 10-9.
39. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38: 191-204.
40. Prange E. Epilepsie bei älteren Patienten. Psychoneuro 2004; 30: 66.
41. Privitera MD. Evidence-based use of topiramate in epilepsy. Lecture. 25th Int Epilepsy Congress. October 14, 2003, Lisbon (Symposium "Challenges to the traditional paradigms of epilepsy management").
42. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. for the EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: a double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-75.
43. Reife RA, Pledger G, Doose D, Lim P, Ward C. Topiramate: PK/PD Analyses. Epilepsia 1995; 36 (suppl 3): S152.
44. Reife RA, Lim P, Pledger G. Topiramate: side effect profile in double-blind studies. Epilepsia 1995; 36 (suppl 4): 34.
45. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41 (suppl 1): S66-S71.
46. Reith D, Burke C, Appleton DB, Wallace G, Pelekanos J. Tolerability of topiramate in children and adolescents. J Pediatr Child Health 2003; 39: 416-9.
47. Ritter F, Glauser TA, Elterman RD, Wyllie E, Topiramate YP Study Group. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Epilepsia 2000; 41 (suppl 1): S82-S85.
48. Rosenfeld WE, Kanner A, Jacobson M, Kretschmar P, PADS Investigator Group. Topiramate and concomitant weight loss. Epilepsia 1997; 38 (suppl 8): 98.
49. Sachdeo RC. Topiramate. Clinical profile in epilepsy. Clin Pharmacokinet 1998; 34: 335-46.
50. Sander JWAS, Arroyo S, Privitera M, Squires L, Wang S, Twyman R. Topiramate in newly diagnosed epilepsy: 100mg/day as initial target dose. Epilepsia 2003; 44 (suppl 8): 82.
51. Schreiner A. Efficacy and tolerability of topiramate as first-line add-on therapy for epilepsy. Epilepsia 2003; 44 (suppl 8): 173.
52. Schreiner A. Efficacy and tolerability of topiramate as early add-on therapy in 450 patients with epilepsy. Epilepsia 2003; 44 (suppl 9): 103-4.
53. Stefan H. Neue Antikonvulsiva: Zweite Generation. Arzneimitteltherapie 2003; 21: 373-84.
54. Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000; 41: 977-80.
55. Sziklas VG, Montour-Proulx I, Andermann F, Dubeau F, Jones-Gotman M. Cognitive effects of topiramate therapy in patients with intractable partial epilepsy. Epilepsia 1999; 40 (suppl 7): 56.
56. Thompson PJ, Baxendale SA, Duncan JS, Sander LJWA. Changes in intellect and verbal processing in association with topiramate treatment. Epilepsia 1999; 40 (suppl 7): 50.
57. Topamax®-Fachinformation/Product monograph. Janssen-Cilag, July 2003.
58. Trimble M, Mula M, Sander J, Thompson P. Word-finding difficulties and topiramate. Epilepsia 2003; 44 (suppl 9): 298.
59. Widmann G, Bien CG, Scherrmann J, Elger CE. Klinische Erfahrungen mit Topiramat. Eine offene, retrospektive Untersuchung an 154 Patienten. Z Epileptol 2002; 15: 17-22.